US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.87

-0.2800-1.11%

Post-market: 24.870.00000.00%19:30 EDT

Volume:23.02K

Turnover:576.09K

Market Cap:57.70M

PE:- -

High:25.58

Open:25.53

Low:24.67

Close:25.15

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.72

T/O Rate:0.99%

Dividend:1.71

Dividend Rate:6.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007

Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY

How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions

Simply Wall St.

Pacific Edge shareholders back governance moves and capital raisings at 2026 meeting

Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer

Cullinan, Taiho say results of Phase 3 trial selected for presentation

Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial

Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Amylyx announces Lucidity Phase 3 trial met primary endpoint

NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

NRX Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate

Benzinga Earnings

NRX Pharmaceuticals (Nasdaq:Nrxp) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17TH at 4:30Pm Et

THOMSON REUTERS

NRX Pharmaceuticals - Reports Cash and Cash Equivalents of $26.70 Mln as of June 30, 2026

THOMSON REUTERS

Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/PSIL/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.87,"timestamp":1789761600000,"preClose":25.15,"halted":0,"volume":23017,"hourTrading":{"tag":"盘后","latestPrice":24.87,"preClose":24.87,"latestTime":"19:30 EDT","volume":13,"amount":323.31,"timestamp":1789774204499,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011133200795228533,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Market Closed","change":-0.28,"latestTime":"09-18 16:00:00 EDT","open":25.53,"high":25.58,"low":24.67,"amount":576091.019912,"amplitude":0.036183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":25.15,"sharesOutstanding":1184976,"nav":24.676,"aum":57248825.63,"dividendRate":0.068565,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.86,"preClose":25.15,"latestTime":"09:17 EDT","volume":28,"amount":719.9700200000001,"timestamp":1789737431335,"change":0.71,"changeRate":0.028231,"amplitude":0.020278},"postHourTrading":{"tag":"盘后","latestPrice":24.87,"preClose":24.87,"latestTime":"19:30 EDT","volume":13,"amount":323.31,"timestamp":1789774204499,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7196050720575493,"impliedVol":0.3416,"impliedVolPercentile":0.4661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7196050720575493,"shares":2319976,"dividePrice":1.7052,"high":25.58,"amplitude":0.036183,"preClose":25.15,"low":24.67,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.87,"eps":0,"divideRate":0.068565,"volume":23017,"delay":0,"ttmEps":0,"open":25.53,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.7682,"twentyDayClose":25.95,"sixtyDayClose":21.7221},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661302932","title":"CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007","url":"https://stock-news.laohu8.com/highlight/detail?id=2661302932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661302932?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:07","pubTimestamp":1787263635,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( ($HK:2616) ) just unveiled an announcement. CStone Pharmaceuticals has secured rapid investigational new drug approval in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","BK4231","TBXU","BK4080","PSIL","IND","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661975236","title":"Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661975236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661975236?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:30","pubTimestamp":1787243423,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Study Overview: Bayer has updated results from a terminated Phase 2 trial of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-adempas-trial-update-what-a-terminated-heart-lung-study-means-for-bayry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-adempas-trial-update-what-a-terminated-heart-lung-study-means-for-bayry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BBC","BAYRY","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660238944","title":"How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2660238944","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660238944?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:39","pubTimestamp":1787233192,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, COMPASS Pathways plc announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site randomized controlled trial testing its COMP360 psilocybin in veterans with treatment-resistant depression, including those with concurrent PTSD, while also presenting at Stifel’s 2026 Biotech Summer Summit in Newport, Rhode Island.\nThe VA collaboration highlights federal interest in evaluating COMP360 within a large veteran population, potentially...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/how-compass-pathways-va-psilocybin-trial-cmps-has-reframed-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/how-compass-pathways-va-psilocybin-trial-cmps-has-reframed-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660240325","title":"Pacific Edge shareholders back governance moves and capital raisings at 2026 meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2660240325","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660240325?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:18","pubTimestamp":1787203086,"startTime":"0","endTime":"0","summary":"Pacific Edge Limited ( ($NZ:PEB) ) has issued an announcement. Shareholders of cancer diagnostics company Pacific Edge approved all six resolutions...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pacific-edge-shareholders-back-governance-moves-and-capital-raisings-at-2026-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pacific-edge-shareholders-back-governance-moves-and-capital-raisings-at-2026-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK8033","PEB.NZ","BMED","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422820","title":"Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422820","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422820?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:16","pubTimestamp":1787156173,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) skyrocketed 133% on Wednesday after new data from a cancer vaccine Phase 3 trial showed strong results. Today’s gain marks one of t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4501","LGHT","BK4139","MRNX","BBC","BK4533","BK4585","GNOM","BK4534","PSIL","BK4548","BK4568","BK4588","MRNY","MRNA","BK4532","WDNA","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422315","title":"Cullinan, Taiho say results of Phase 3 trial selected for presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422315?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:10","pubTimestamp":1787155816,"startTime":"0","endTime":"0","summary":"Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BBC","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660538426","title":"Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660538426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660538426?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:36","pubTimestamp":1787146574,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals (BDRX) announced that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSIL","BDRX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425479","title":"Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425479","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425479?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:15","pubTimestamp":1787145349,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421486","title":"Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421486","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421486?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:30","pubTimestamp":1787142600,"startTime":"0","endTime":"0","summary":"August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347617/0/en/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","PSIL","BK4195","BBC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461075","title":"Amylyx announces Lucidity Phase 3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461075","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461075?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:06","pubTimestamp":1787051213,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","AMLX","BK4007","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469854","title":"NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469854?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:09","pubTimestamp":1787047740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","PSIL","IBRN","ALKS","PSCH","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660292438","title":"NRX Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2660292438","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660292438?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:33","pubTimestamp":1786973588,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryNRX Pharmaceuticals IncNRXP.OQreported a quarterly adjusted loss of 44 cents per share for the quarter ended Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL8N44E0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660904484","title":"NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660904484","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660904484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:07","pubTimestamp":1786964859,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61241856/nrx-pharmaceuticals-q2-eps-0-44-misses-0-06-estimate-sales-1-101m-miss-17-488m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660843574","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17TH at 4:30Pm Et","url":"https://stock-news.laohu8.com/highlight/detail?id=2660843574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660843574?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA5NRC6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660649484","title":"NRX Pharmaceuticals - Reports Cash and Cash Equivalents of $26.70 Mln as of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660649484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660649484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA5NRC6D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484873","title":"Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484873","media":"Dow Jones","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484873?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964400,"startTime":"0","endTime":"0","summary":"Key recent and second quarter highlights include:-- Completed first-cycle FDA review of the Company's ANDA for. preservative-free ketamine with no drug-related major deficiencies. The. sole remaining item, a manufacturer's attestation on the vial, has been. -- Initiation of commercial scale manufacturing of preservative-free. ketamine building to launch stock of 5 million doses to be ready for. -- Selected by the Defense Advanced Research Projects Agency  as. prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of. NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5. -- The Company is advancing its NRX-100 NDA on Real World Evidence from more. than 65,000 patients, leveraging a Presidential Executive Order and. Congressional budget language that encourage FDA use of such evidence in. -- Closed an institutionally-supported, underwritten public offering of. common stock for gross proceeds of $22.3 million, including full exercise. of the underwriters' opti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","AMLP","EIPX","R","EMLP","EIPI","NQmain","BK4144","BK4588","BK4581","MLPA","UMI","TPZ","BK4022","ET","LABU","BK4561","BK4232","BK4590","MDST","ENFR","TNGY","USAI","AMZA","NRXP","BK4585","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609102","title":"argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609102?lang=en_us&edition=fundamental","pubTime":"2026-08-17 13:39","pubTimestamp":1786945177,"startTime":"0","endTime":"0","summary":"arGEN X ( ($GB:0QW0) ) has shared an announcement. argenx has reported positive topline results from its ALKIVIA Phase 3 trial of VYVGART Hytrulo i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","IMNM","SOCL","BK4139","BK4563","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410575","title":"Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410575?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:50","pubTimestamp":1786927814,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","MSB","BK4139","BK4006","MESO","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105196","title":"Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105196","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660105196?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:24","pubTimestamp":1786926259,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial testing ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","PSIL","BK4139","BBC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}